| Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate … VD Handratta, TS Vasaitis, VCO Njar, LK Gediya, R Kataria, P Chopra, ... Journal of medicinal chemistry 48 (8), 2972-2984, 2005 | 331 | 2005 |
| Promise and challenges in drug discovery and development of hybrid anticancer drugs LK Gediya, VCO Njar Expert opinion on drug discovery 4 (11), 1099-1111, 2009 | 226 | 2009 |
| Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases VCO Njar, L Gediya, P Purushottamachar, P Chopra, TS Vasaitis, ... Bioorganic & medicinal chemistry 14 (13), 4323-4340, 2006 | 205 | 2006 |
| Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16 … T Vasaitis, A Belosay, A Schayowitz, A Khandelwal, P Chopra, LK Gediya, ... Molecular cancer therapeutics 7 (8), 2348-2357, 2008 | 169 | 2008 |
| A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate … LK Gediya, P Chopra, P Purushottamachar, N Maheshwari, VCO Njar Journal of medicinal chemistry 48 (15), 5047-5051, 2005 | 131 | 2005 |
| Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to … P Purushottamachar, AM Godbole, LK Gediya, MS Martin, TS Vasaitis, ... Journal of medicinal chemistry 56 (12), 4880-4898, 2013 | 126 | 2013 |
| Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and … RD Bruno, TS Vasaitis, LK Gediya, P Purushottamachar, AM Godbole, ... Steroids 76 (12), 1268-1279, 2011 | 96 | 2011 |
| 4-Pregnen-21-ol-3, 20-dione-21-(4-bromobenzenesufonate)(NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors TS Dexheimer, LK Gediya, AG Stephen, I Weidlich, S Antony, C Marchand, ... Journal of medicinal chemistry 52 (22), 7122-7131, 2009 | 71 | 2009 |
| Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro … JB Patel, CK Huynh, VD Handratta, LK Gediya, AMH Brodie, ... Journal of medicinal chemistry 47 (27), 6716-6729, 2004 | 71 | 2004 |
| Three-dimensional quantitative structure activity relationships (3-D-QSAR) of antihyperglycemic agents SS Kulkarni, LK Gediya, VM Kulkarni Bioorganic & medicinal chemistry 7 (7), 1475-1485, 1999 | 71 | 1999 |
| First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast … S Ramalingam, L Gediya, AK Kwegyir-Afful, VP Ramamurthy, ... Oncotarget 5 (2), 530, 2014 | 67 | 2014 |
| Improved synthesis of histone deacetylase inhibitors (HDIs)(MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of … LK Gediya, A Belosay, A Khandelwal, P Purushottamachar, VCO Njar Bioorganic & medicinal chemistry 16 (6), 3352-3360, 2008 | 62 | 2008 |
| The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer K Tran, R Risingsong, D B. Royce, CR Williams, MB Sporn, PA Pioli, ... Carcinogenesis 34 (1), 199-210, 2013 | 53 | 2013 |
| Design, Synthesis, and Evaluation of Novel Mutual Prodrugs (Hybrid Drugs) of All-trans-Retinoic Acid and Histone Deacetylase Inhibitors with Enhanced … LK Gediya, A Khandelwal, J Patel, A Belosay, G Sabnis, J Mehta, ... Journal of medicinal chemistry 51 (13), 3895-3904, 2008 | 51 | 2008 |
| Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent P Purushottamachar, A Khandelwal, TS Vasaitis, RD Bruno, LK Gediya, ... Bioorganic & medicinal chemistry 16 (7), 3519-3529, 2008 | 39 | 2008 |
| The retinamide VNLG‐152 inhibits f‐AR/AR‐V7 and MNK–eIF 4E signaling pathways to suppress EMT and castration‐resistant prostate cancer xenograft growth VP Ramamurthy, S Ramalingam, LK Gediya, VCO Njar The FEBS journal 285 (6), 1051-1063, 2018 | 35 | 2018 |
| First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents P Purushottamachar, A Khandelwal, P Chopra, N Maheshwari, LK Gediya, ... Bioorganic & medicinal chemistry 15 (10), 3413-3421, 2007 | 35 | 2007 |
| HDAC inhibitors and hormone targeted drugs for the treatment of cancer A Brodie, V Njar, G Sabnis, L Gediya US Patent 8,110,550, 2012 | 31 | 2012 |
| Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines VP Ramamurthy, S Ramalingam, L Gediya, AK Kwegyir-Afful, VCO Njar Oncotarget 6 (5), 3195, 2015 | 26 | 2015 |
| MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours A Khandelwal, LK Gediya, VCO Njar British journal of cancer 98 (7), 1234-1243, 2008 | 25 | 2008 |
